Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02841033 · ClinicalTrials.gov registry record · Phase 1
Daratumumab for the Treatment of Patients With AL Amyloidosis
A Phase 1 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02841033 is a Phase 1 study that has completed, run by Boston Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT02841033, a Phase 1 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month. Study treatment may continue until disease progression, unacceptable toxicity, or decision to withdraw from the trial. Disease evaluations will be performed every three months until disease progression.
Interventions
- DRUG daratumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2020-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02841033
The ClinicalTrials.gov registry entry for NCT02841033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which daratumumab is the first listed.
NCT02841033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02841033 about?
NCT02841033 is a clinical study titled "Daratumumab for the Treatment of Patients With AL Amyloidosis". Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month. Study treatment may continue until disease progression, unacceptable toxicity, or decision to withdraw from the trial. Disease evalu...
What is the current status of trial NCT02841033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-03-20. Estimated completion is 2020-07-17.
What interventions are being tested in trial NCT02841033?
The interventions under investigation include: daratumumab (DRUG).
Who is sponsoring clinical trial NCT02841033?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.